BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:872-81. [PMID: 33932268 DOI: 10.1002/ejhf.2206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Escobar C, Luis-Bonilla J, Crespo-Leiro MG, Esteban-Fernández A, Farré N, Garcia A, Nuñez J. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. Expert Opin Pharmacother 2022. [PMID: 35995759 DOI: 10.1080/14656566.2022.2116275] [Reference Citation Analysis]
2 Aceña A, de Juan Bagudá J, Rincón LM. Personalized Therapy and Clinical Outcome for Heart Failure. JCM 2022;11:4851. [DOI: 10.3390/jcm11164851] [Reference Citation Analysis]
3 Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis? J Am Coll Cardiol 2022;80:595-7. [PMID: 35926932 DOI: 10.1016/j.jacc.2022.05.028] [Reference Citation Analysis]
4 Moloce MA, Costache II, Nicolae A, Onofrei Aursulesei V. Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. Life (Basel) 2022;12:1112. [PMID: 35892914 DOI: 10.3390/life12081112] [Reference Citation Analysis]
5 Masarone D, Kittleson MM, Martucci ML, Valente F, Gravino R, Verrengia M, Ammendola E, Contaldi C, Di Palma V, Caiazzo A, Petraio A, Pollesello P, Pacileo G. Levosimendan as a “Bridge to Optimization” in Patients with Advanced Heart Failure with Reduced Ejection—A Single-Center Study. JCM 2022;11:4227. [DOI: 10.3390/jcm11144227] [Reference Citation Analysis]
6 Ramos R, Moliner P, Comin-Colet J. Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice. Eur J Intern Med 2022:S0953-6205(22)00238-2. [PMID: 35787970 DOI: 10.1016/j.ejim.2022.06.019] [Reference Citation Analysis]
7 Anguita-Sánchez M, González-Costello J, Recio-Mayoral A, Rodríguez-Lambert JL, Iñiguez-Romo A, Ruiz-Mateas F, Elola-Somoza J; Board of the Spanish Society of Cardiology. Centres of excellence in heart failure: results of an accreditation programme in Spain (2017-2021). ESC Heart Fail 2022. [PMID: 35778850 DOI: 10.1002/ehf2.14029] [Reference Citation Analysis]
8 Cox ZL, Nandkeolyar S, Johnson AJ, Lindenfeld J, Rali AS. In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. Card Fail Rev 2022;8:e21. [DOI: 10.15420/cfr.2022.08] [Reference Citation Analysis]
9 . Comentarios a la guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022;75:458-65. [DOI: 10.1016/j.recesp.2021.11.012] [Reference Citation Analysis]
10 Shen X, Shen X. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction. ESC Heart Fail 2022. [PMID: 35642772 DOI: 10.1002/ehf2.14005] [Reference Citation Analysis]
11 Tomasoni D, Adamo M, Metra M. June 2022 at a glance: prevention, outcomes and treatment. Eur J Heart Fail 2022;24:913-5. [PMID: 35796283 DOI: 10.1002/ejhf.2232] [Reference Citation Analysis]
12 SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee. Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 2022;75:458-65. [PMID: 35190290 DOI: 10.1016/j.rec.2021.11.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol 2022;45 Suppl 1:S26-30. [PMID: 35789017 DOI: 10.1002/clc.23847] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Berezin AE, Berezin AA. Point-of-care heart failure platform: where are we now and where are we going to? Expert Rev Cardiovasc Ther 2022. [PMID: 35588730 DOI: 10.1080/14779072.2022.2080657] [Reference Citation Analysis]
15 Tomasoni D, Adamo M, Metra M. April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction. Eur J Heart Fail 2022;24:593-5. [PMID: 35545950 DOI: 10.1002/ejhf.2228] [Reference Citation Analysis]
16 Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, Zieroth S, Butler J. Optimizing Foundational Therapies in Patients With HFrEF. JACC: Basic to Translational Science 2022;7:504-17. [DOI: 10.1016/j.jacbts.2021.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Stolfo D, Sinagra G, Savarese G. Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. Card Fail Rev 2022;8:e12. [DOI: 10.15420/cfr.2021.34] [Reference Citation Analysis]
18 Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, Carr RD, Ceriello A, Forst T, Giorgino F, Guerci B, Heerspink HJL, Itzhak B, Ji L, Kosiborod M, Lalić N, Lehrke M, Marx N, Nauck M, Rodbard HW, Rosano GMC, Rossing P, Rydén L, Santilli F, Schumm-Draeger PM, Vandvik PO, Vilsbøll T, Wanner C, Wysham C, Standl E. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol 2022;21:50. [PMID: 35395808 DOI: 10.1186/s12933-022-01481-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tomasoni D, Adamo M, Metra M. March 2022 at a glance: focus on medical therapy, prevention and comorbidities. Eur J Heart Fail 2022;24:403-5. [PMID: 35384200 DOI: 10.1002/ejhf.2226] [Reference Citation Analysis]
20 González-juanatey J, Anguita-sánchez M, Bayes-genís A, Comín-colet J, García-quintana A, Recio-mayoral A, Zamorano-gómez J, Cepeda-rodrigo J, Manzano L. Vericiguat in heart failure: From scientific evidence to clinical practice. Revista Clínica Española (English Edition) 2022. [DOI: 10.1016/j.rceng.2021.12.006] [Reference Citation Analysis]
21 Tran B, Serag-bolos ES, Fernandez J, Miranda AC. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. Journal of Pharmacy Practice. [DOI: 10.1177/08971900221087096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F, Metra M. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 2022. [PMID: 35352499 DOI: 10.1002/ehf2.13859] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Berezin AE, Mozos I, Petrovič D. Editorial: Epigenetics in Heart Failure Developing: The Orchestra of Etiology and Comorbidities. Front Cardiovasc Med 2022;9:869613. [DOI: 10.3389/fcvm.2022.869613] [Reference Citation Analysis]
24 Herrmann E, Huisl P, Aßmus B. [Novel European Heart Failure Guidelines - Change in Treatment Paradigms]. Dtsch Med Wochenschr 2022;147:326-31. [PMID: 35291038 DOI: 10.1055/a-1609-2469] [Reference Citation Analysis]
25 Severino P, D’amato A, Prosperi S, Dei Cas A, Mattioli AV, Cevese A, Novo G, Prat M, Pedrinelli R, Raddino R, Gallina S, Schena F, Poggesi C, Pagliaro P, Mancone M, Fedele F; on behalf of the Italian National Institute for Cardiovascular Research (INRC). Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity? JCM 2022;11:857. [DOI: 10.3390/jcm11030857] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
26 Abdelhamid M, Kandil H, Hassanin M, Shaheen S, Sobhy M, ElEtreby A, Hasan-Ali H, Mahfouz H, Nasr G, Shawky I, Emil S, ElSetiha M, Hasssan M, Sadek Y, Karim MA, Asham A, Ghaleb M, Samir A, Shokry K. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2022. [PMID: 35118822 DOI: 10.1002/ehf2.13811] [Reference Citation Analysis]
27 Shanmugam N. The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics. Eur Cardiol 2022;17:e01. [DOI: 10.15420/ecr.2021.57] [Reference Citation Analysis]
28 Tomasoni D, Adamo M, Metra M. January 2022 at a glance: time for the new ESC guidelines on heart failure. Eur J Heart Fail 2022;24:1-3. [PMID: 35083828 DOI: 10.1002/ejhf.2222] [Reference Citation Analysis]
29 Raschi E, Diemberger I, Sabatino M, Poluzzi E, De Ponti F, Potena L. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opin Pharmacother 2022;:1-18. [PMID: 35050813 DOI: 10.1080/14656566.2022.2027909] [Reference Citation Analysis]
30 Arutyunov GP, Lopatin YM, Ametov AS, Ageev FT, Antsiferov MB, Villevalde SV, Vinogradova NG, Galstyan GR, Galyavich AS, Gilyarevskiy SR, Glezer MG, Zhirov IV, Ilyin MV, Lebedeva AI, Nedogoda SM, Salukhov VV, Tarlovskaya EI, Tereshchenko SN, Fomin IV, Khalimov IS, Khasanov NR, Cherkashin DV, Yakushin SS. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii arkhiv 2022;93:1491-7. [DOI: 10.26442/00403660.2021.12.201281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J 2022:ehab887. [PMID: 34974611 DOI: 10.1093/eurheartj/ehab887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Blair HA. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. Am J Cardiovasc Drugs 2021;21:701-10. [PMID: 34651263 DOI: 10.1007/s40256-021-00503-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Severino P, D'Amato A, Prosperi S, Costi B, Angotti D, Birtolo LI, Chimenti C, Lavalle C, Maestrini V, Mancone M, Fedele F. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Fail Rev 2021. [PMID: 34654997 DOI: 10.1007/s10741-021-10170-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
34 Rosano GMC, Allen LA, Abdin A, Lindenfeld J, O'Meara E, Lam CSP, Lancellotti P, Savarese G, Gottlieb SS, Teerlink J, Wintrich J, Böhm M. Drug Layering in Heart Failure: Phenotype-Guided Initiation. JACC Heart Fail 2021;9:775-83. [PMID: 34627725 DOI: 10.1016/j.jchf.2021.06.011] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
35 Fucili A, Cimaglia P, Severi P, Giannini F, Boccadoro A, Micillo M, Rapezzi C, Tavazzi L, Ferrari R. Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease? J Clin Med 2021;10:4325. [PMID: 34640341 DOI: 10.3390/jcm10194325] [Reference Citation Analysis]
36 Silva-Cardoso J, Fonseca C, Franco F, Morais J, Ferreira J, Brito D. Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Rev Port Cardiol (Engl Ed) 2021:S0870-2551(21)00355-3. [PMID: 34462172 DOI: 10.1016/j.repc.2021.07.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Nessler J. Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction - a practical approach. Postepy Kardiol Interwencyjnej 2021;17:135-40. [PMID: 34400915 DOI: 10.5114/aic.2021.107491] [Reference Citation Analysis]
38 Tomasoni D, Adamo M, Metra M. June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. Eur J Heart Fail 2021;23:847-9. [PMID: 34271596 DOI: 10.1002/ejhf.1884] [Reference Citation Analysis]